welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
NIH Awards $86 Million to Improve Genome Editing Techniques
Somatic Cell Genome Editing support is aimed at improving therapeutic options for both rare and common diseases.
Making changes to a patients DNA can have powerful implications for the treatment of disease. To tap into this immense potential, NIH recently awarded 21 Somatic Cell Genome Editing grants — totaling approximately $86 million over the next five years, pending available funds — to support research aimed at improving methods to edit the human genome. These grants are the first to be awarded through the Somatic Cell Genome Editing (SCGE) program, which was launched in January 2018 with NIH Common Fund support. As a trans-NIH endeavor, SCGE is managed by staff from multiple NIH Institutes and Centers, with leadership from NCATS.
rareRelated
-
Local boy with Duchenne muscular dystrophy begins promising gene-targeted therapySeven-year-old Wyatt Hubbard was a bit t...
-
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017We issued an updated research report on ...
-
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
-
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The main purposes of this study are to s...
-
Body Composition and Body Mass Index in Duchenne Muscular Dystrophy: Role of Dietary IntakeIntroduction: In Duchenne muscular dyst...
-
A Study of Tadalafil for Duchenne Muscular DystrophyThe main purpose of this study is to det...
-
AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with co...Duchenne muscular dystrophy (DMD) is one...
-
Cardiac management of the patient with Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) result...
